Depending on the selected first indication to be pursued and the results of the clinical trials throughout the development of ACT-903, ACT plans to apply for all relevant FDA designations and programs. These potential programs include Orphan Drug Designation (ODD), Fast Track Designation (FTD), Breakthrough Therapy Designation (BTD) Accelerated Approval (AP) and/or Priority BLA Review (PR).